Skip to main content

Advertisement

Figure 4 | Arthritis Research & Therapy

Figure 4

From: Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus

Figure 4

Epratuzumab increases the motility of the B-cells. To evaluate the functionality of β1 integrin on the B-cells, we checked the capacity of B-cells to transmigrate through fibronectin independently of chemoattractant, with epratuzumab incubation (data from nine independent experiments are shown in Figure 4). Epratuzumab caused an enhanced transmigration through fibronection layers; indeed, a threefold greater basal motility of treated CD27negative B-cells was observed.

Back to article page